Brightside Health is a technology company.
Brightside Health has raised $109.0M across 4 funding rounds.
Brightside Health has raised $109.0M in total across 4 funding rounds.
Brightside Health is a San Francisco-based telemedicine company founded in 2017 that delivers personalized, evidence-based mental health care for depression, anxiety, and other mood disorders, including severe cases and suicide risk, via a tech-enabled platform.[1][2][3][4] It combines precision psychiatry, clinically-proven therapy (like the Unified Protocol and CBT), and tools such as AI-driven monitoring, video visits, unlimited messaging, and proactive check-ins to achieve high outcomes—86% of patients show significant improvement within 12 weeks and 71% reach remission—serving individuals across the full symptom spectrum from home, now accessible to over 100 million covered lives through partnerships with Cigna, Aetna, UnitedHealthcare, Medicare, and Medicaid.[1][4][5][6] The company addresses access barriers in mental health by making expert care affordable, scalable, and effective, with strong growth via $17M Series A (Feb 2021) and $50M Series B (Nov 2021) funding, expanding from 57 to 175 employees.[1][5]
Brightside Health was co-founded in 2017 by CEO Brad Kittredge and Chief Medical Officer Mimi Winsberg, MD, driven by personal family experiences with inadequate mental health care, including trial-and-error medications and ineffective therapy without plans.[1][4][5] The idea emerged from frustration with traditional systems' limitations, aiming to create precision treatment at scale using technology to personalize care and track progress, surpassing in-office quality.[1] Early traction built quickly: launching core services, securing Series A funding in Feb 2021, partnering with Cigna and Aetna (Jun 2021) to cover 55M lives, followed by Series B in Nov 2021, UnitedHealthcare partnership (Jun 2022) expanding to 65M lives, HITRUST certification (Nov 2022), Suicide Prevention Program (formerly Crisis Care) in Dec 2022 based on the CAMS framework, and Medicare/Medicaid deals in Oct 2023 reaching 100M+ lives—pivotal moments scaling impact amid rising mental health demand.[1][4]
Brightside rides the telemental health boom, accelerated by pandemic-driven demand and awareness of the suicide epidemic, where traditional care fails high-risk patients (e.g., mismatched settings for suicide risk).[1][2][4] Timing aligns with remote work normalization, AI/healthtech maturation, and insurer shifts to value-based care—Brightside's outcomes data (71% remission) positions it to influence payers toward tech-precision models over volume-based therapy.[4][5] Market forces like clinician shortages and 30+ years of underfunded mental health amplify its edge, as fully remote operations break geographic barriers, serving complex cases at scale.[1][2] It shapes the ecosystem by pioneering programs like Crisis Care, inspiring clinician empowerment, and pushing HITRUST-secured standards, contributing to a $200B+ U.S. mental health market projected for digital disruption.[1][4]
Brightside is poised to dominate telepsychiatry with its outcomes-proven model, likely expanding AI for predictive interventions and clinician tools amid workforce growth and payer wins.[1][2][5] Trends like AI personalization, remote care mandates, and suicide prevention focus will propel it toward 100% improvement goals, potentially via Series C funding or acquisitions, evolving influence from access provider to ecosystem leader in precision mental health—transforming lives as it started, from family struggles to nationwide scale.[4][5]
Brightside Health has raised $109.0M in total across 4 funding rounds.
Brightside Health's investors include 7wire Ventures, Accomplice, Accomplice VC, ACME Capital, FirstMark Capital, Frederique Dame, Ingeborg Investments, Lux Capital, Maveron, McCarthy Capital, OMERS Ventures, Practical Venture Capital.
Brightside Health has raised $109.0M across 4 funding rounds. Most recently, it raised $33.0M Series C in March 2024.